Replies to post #59912 on Biotech Values

[DewDiligence]

IDIX ReadMeFirst

[Updated for 4Q07 results and Susquehanna webcast.]


What is IDIX’s business all about?
Susquehanna webcast (3/4/08)
Business description from 10K
#msg-26915744 Addressable markets for antiviral drugs
#msg-26915852 Drug portfolio
#msg-25841903 IDIX is back in the HCV arena!


Valuation and finances
#msg-25899731 What’s not to like?
#msg-22707854 Valuation is cheap!
#msg-25870940 IDIX vs VRUS
#msg-27413201 4Q07 financial results


Upcoming events
#msg-27346596 2008-2009 clinical goals


Officers, directors, and major shareholders
#msg-27286093 Composition of Board of Directors
Capsule résumés of executive officers (click on a name)
#msg-27350482 Insider shareholdings
#msg-22707884 Protection from hostile takeover


Development program in HIV
#msg-26606685 IDX899 data from CROI
#msg-26884307 IDX899 holds its own on antiviral potency
#msg-26915885 IDX899 development program
#msg-25885594 Musings on size of an HIV partnership
#msg-26915744 HIV addressable market
#msg-26220473 HIV market in Europe’s Big-5 countries
#msg-24139072 Increased HIV screening will expand market
#msg-26915314 IDX899 seeks to supersede Sustiva
#msg-26800695 Why is IDIX testing lower doses?
#msg-26446326 Sustiva (the top NNRTI) sells more than $1B/yr
#msg-24329960 IDX899 has no cross-resistance to Sustiva
#msg-24673329 HIV competitive landscape
#msg-21895680 Importance of qD dosing
#msg-26126733 FDA approves Intelence (TMC125)
#msg-26643515 Intelence 48w data in NNRTI-refractory HIV
#msg-26610262 Pfizer’s UK 453,061
#msg-25649546 Ardea’s RDEA806
#msg-23282517 Miscellaneous early-stage NNRTI’s


Development program in HCV
#msg-25841903 IDIX is back in the HCV arena!
#msg-25802238 IDX184 selected as lead candidate
#msg-26915921 How is IDX184 better than NM283?
#msg-26915744 HCV addressable market
#msg-26640965 HCV competitive landscape for new agents


Tyzeka/Sebivo commercial program in HBV
#msg-23242360 Restructuring of Tyzeka relationship with NVS
#msg-24405569 Twelve different royalty tiers
#msg-23249593 Conjecture on the royalty rates
#msg-26915744 HBV addressable market
#msg-23785846 Status of European launch
#msg-23434932 Treating asymptomatic e- patients will boost market
#msg-11099728 Asian immigrants are largely untreated
#msg-21358606 Why a slow sales ramp for new HBV drugs?
#msg-21388028 Bearish opinion by ‘gofishmarko’


Tyzeka clinical data
#msg-14377860 Two-year data from GLOBE trial
#msg-22771520 Tyzeka studies in progress
#msg-12271882 Tyzeka resistance data
#msg-14404551 Tyzeka’s efficacy comparable to Baraclude’s (1)
#msg-18389527 Tyzeka’s efficacy comparable to Baraclude’s (2)
http://www.fda.gov/cder/foi/label/2006/022011lbl.pdf FDA product label


Competitive landscape in HBV: general
#msg-21652956 Prices of HBV drugs


Competitive landscape in HBV: Baraclude
#msg-22555240 Baraclude studies in progress
#msg-21652925 Baraclude’s black-box warning for HIV/HBV co-infection
#msg-21678537 Size of HIV/HBV co-infection market
#msg-21678801 Tyzeka’s edge in pre-menopausal women
#msg-23241377 Three-year Baraclude resistance data
#msg-26442186 Current Baraclude sales
#msg-26443005 Baraclude sales ramp 2005-present


Competitive landscape in HBV: Viread/Truvada, Hepsera
#msg-24255644 Phase-3 Viread data
#msg-22555241 Viread/Truvada studies in progress
#msg-21460468 GILD to cease promotion of Hepsera when Viread approved
#msg-26221188 Current Hepsera sales


Competitive landscape in HBV: Clevudine
#msg-23309283 Global phase-3 program
#msg-23359068 Musings on sustained virologic response (SVR)
#msg-14328142 Clinical results from Korea
#msg-20218516 Clevudine, Tyzeka are structurally similar


Educational Links
http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm
http://www.who.int/mediacentre/factsheets/fs204/en
http://www.idenix.com/about/media/Glossary_of_terms.pdf
http://www.idenix.com/hepb/about
http://www.idenix.com/hiv/about
http://www.idenix.com/hepc/about
http://www.hivandhepatitis.com
http://www.hepfi.org
http://www.hcvdrugs.com/